EL7.AI
StocksUpdated•Originally published 7 June 2026•Updated 7 June 2026•
1 min read

Gilead Sciences Beats Earnings Estimates Amid Major Institutional Sell-Off

Key Facts

1DB&C Advisors LLC acquired 12,783 shares of Gilead Sciences, Inc. during the fourth quarter.
2The new investment is valued at approximately $1.57 million, making it the 16th largest holding in the firm's portfolio.
3GILD stock holds a 'Moderate Buy' consensus rating with an average target price of $156.93.

Reflecting a divergence in institutional sentiment toward the biotech sector, Gilead Sciences reported strong quarterly financial results that surpassed analyst estimates. The company achieved an earnings per share (EPS) of $2.03, driven by a 4.4% year-over-year revenue increase, while management approved a quarterly dividend of $0.82 per share. However, the shareholder base saw a significant shift as Los Angeles Capital Management liquidated 676,504 shares, a move that vastly outweighs recent smaller institutional entries into the stock.

This financial outperformance occurs as the healthcare sector navigates margin pressures; for instance, peer company Amgen (AMGN) reported a 22% revenue jump in its latest earnings report, signaling broader sector momentum. Per market data, GILD's 4.4% growth rate reinforces its position as a stable cash-flow generator, despite the conflicting signals from major fund managers regarding their long-term holdings in the company.

Regarding technical performance, GILD closed at $129.16 (close June 05, 2026), remaining below the consensus analyst price target of $156.93. Investors should monitor the impact of the $0.82 dividend payment on price action, alongside upcoming catalysts such as the US ISM Manufacturing PMI, which could dictate broader risk appetite for large-cap healthcare equities.